|
KR100908114B1
(ko)
*
|
2002-03-09 |
2009-07-16 |
삼성전자주식회사 |
스케일러블 무손실 오디오 부호화/복호화 장치 및 그 방법
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
EP2651442B1
(en)
|
2010-12-14 |
2020-04-22 |
University of Maryland, Baltimore |
Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer
|
|
PL3246416T3
(pl)
|
2011-04-15 |
2024-09-30 |
The Johns Hopkins University |
Bezpieczny system sekwencjonowania
|
|
US9708384B2
(en)
|
2011-09-22 |
2017-07-18 |
The Trustees Of The University Of Pennsylvania |
Universal immune receptor expressed by T cells for the targeting of diverse and multiple antigens
|
|
EP3563872A1
(en)
|
2012-04-05 |
2019-11-06 |
Massachusetts Institute Of Technology |
Immunostimulatory compositions and methods of use thereof
|
|
CN104884095A
(zh)
*
|
2012-07-13 |
2015-09-02 |
宾夕法尼亚大学董事会 |
Cart19用于耗减正常b细胞以诱导耐受的用途
|
|
EP2872218A4
(en)
*
|
2012-07-13 |
2016-07-06 |
Univ Pennsylvania |
COMPOSITIONS AND METHOD FOR REGULATING HAIR GROWTH
|
|
CA2889937C
(en)
|
2012-10-29 |
2020-12-29 |
The Johns Hopkins University |
Papanicolaou test for ovarian and endometrial cancers
|
|
ES2776698T3
(es)
*
|
2012-12-20 |
2020-07-31 |
Purdue Research Foundation |
Células T que expresan un receptor antigénico quimérico como terapia contra el cáncer
|
|
EP2958942B1
(en)
|
2013-02-20 |
2020-06-03 |
Novartis AG |
Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
|
|
ES2760023T3
(es)
|
2013-02-20 |
2020-05-12 |
Univ Pennsylvania |
Tratamiento del cáncer utilizando receptor de antígeno quimérico anti-EGFRvIII humanizado
|
|
EP3811954A1
(en)
|
2013-02-26 |
2021-04-28 |
Memorial Sloan Kettering Cancer Center |
Compositions and methods for immunotherapy
|
|
CN105358156A
(zh)
*
|
2013-03-13 |
2016-02-24 |
密执安大学评议会 |
双重mek/pi3k抑制剂和使用其的治疗方法
|
|
SG11201506974XA
(en)
*
|
2013-03-14 |
2015-10-29 |
Bellicum Pharmaceuticals Inc |
Methods for controlling t cell proliferation
|
|
US9499855B2
(en)
|
2013-03-14 |
2016-11-22 |
Elwha Llc |
Compositions, methods, and computer systems related to making and administering modified T cells
|
|
US9587237B2
(en)
|
2013-03-14 |
2017-03-07 |
Elwha Llc |
Compositions, methods, and computer systems related to making and administering modified T cells
|
|
EP2970426B1
(en)
|
2013-03-15 |
2019-08-28 |
Michael C. Milone |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
|
UY35468A
(es)
|
2013-03-16 |
2014-10-31 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
|
|
US10208125B2
(en)
|
2013-07-15 |
2019-02-19 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Anti-mucin 1 binding agents and uses thereof
|
|
WO2015017214A1
(en)
*
|
2013-07-29 |
2015-02-05 |
Bluebird Bio, Inc. |
Multipartite signaling proteins and uses thereof
|
|
ES2741308T3
(es)
*
|
2013-10-15 |
2020-02-10 |
Scripps Research Inst |
Interruptores de células T con receptores de antígenos quiméricos y usos de los mismos
|
|
ES2845924T3
(es)
*
|
2013-10-15 |
2021-07-28 |
Scripps Research Inst |
Interruptores de células T con receptores de antígenos quiméricos peptídicos y usos de los mismos
|
|
RU2714902C2
(ru)
|
2013-12-19 |
2020-02-20 |
Новартис Аг |
Химерные рецепторы антигена против мезотелина человека и их применение
|
|
CA2933707A1
(en)
*
|
2013-12-20 |
2015-06-25 |
Fred Hutchinson Cancer Research Center |
Tagged chimeric effector molecules and receptors thereof
|
|
EP3087101B1
(en)
|
2013-12-20 |
2024-06-05 |
Novartis AG |
Regulatable chimeric antigen receptor
|
|
EP4303229A3
(en)
|
2014-01-21 |
2024-04-17 |
Novartis AG |
Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
|
|
CN106132423B
(zh)
|
2014-02-14 |
2020-07-31 |
贝里坤制药股份有限公司 |
用诱导型嵌合多肽活化t细胞的方法
|
|
WO2015143224A1
(en)
*
|
2014-03-19 |
2015-09-24 |
Ambrx, Inc. |
Chimeric antigen receptor-modified t-cells
|
|
ES2876263T3
(es)
|
2014-04-07 |
2021-11-12 |
Novartis Ag |
Tratamiento del cáncer usando receptor de antígeno quimérico anti-cd19
|
|
US11030531B2
(en)
|
2014-06-06 |
2021-06-08 |
Trustees Of Boston University |
DNA recombinase circuits for logical control of gene expression
|
|
CN105194661B
(zh)
*
|
2014-06-26 |
2019-05-03 |
科济生物医药（上海）有限公司 |
时空可调性抑制病理性靶细胞的系统
|
|
SG11201700416TA
(en)
|
2014-07-21 |
2017-02-27 |
Novartis Ag |
Treatment of cancer using a cd33 chimeric antigen receptor
|
|
EP3171882A1
(en)
|
2014-07-21 |
2017-05-31 |
Novartis AG |
Treatment of cancer using a cll-1 chimeric antigen receptor
|
|
US11542488B2
(en)
|
2014-07-21 |
2023-01-03 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
US10174095B2
(en)
|
2014-07-21 |
2019-01-08 |
Novartis Ag |
Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor
|
|
WO2016012623A1
(en)
*
|
2014-07-25 |
2016-01-28 |
Theravectys |
Lentiviral vectors for regulated expression of a chimeric antigen receptor molecule
|
|
DK3183268T3
(da)
|
2014-08-19 |
2020-05-11 |
Univ Pennsylvania |
Behandling af cancer ved anvendelse af en cd123-kimær antigenreceptor
|
|
ES2688035T3
(es)
*
|
2014-08-29 |
2018-10-30 |
Gemoab Monoclonals Gmbh |
Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes
|
|
EP3189148A4
(en)
|
2014-09-02 |
2018-05-02 |
Bellicum Pharmaceuticals, Inc. |
Costimulation of chimeric antigen receptors by myd88 and cd40 polypeptides
|
|
KR20210149228A
(ko)
|
2014-09-17 |
2021-12-08 |
노파르티스 아게 |
입양 면역요법을 위한 키메라 수용체에 의한 세포독성 세포의 표적화
|
|
US10774388B2
(en)
|
2014-10-08 |
2020-09-15 |
Novartis Ag |
Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
|
|
DK3597742T3
(da)
*
|
2014-10-09 |
2022-10-03 |
Univ Yamaguchi |
Car-udtrykkende vektor og car-udtrykkende t-celler
|
|
EP3025719B1
(en)
|
2014-11-26 |
2018-09-26 |
Miltenyi Biotec GmbH |
Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases
|
|
RU2751362C2
(ru)
|
2014-12-29 |
2021-07-13 |
Новартис Аг |
Способы получения экспрессирующих химерный антигенный рецептор клеток
|
|
US11459390B2
(en)
|
2015-01-16 |
2022-10-04 |
Novartis Ag |
Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor
|
|
WO2016126608A1
(en)
|
2015-02-02 |
2016-08-11 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
IL254141B
(en)
|
2015-02-27 |
2022-07-01 |
Icell Gene Therapeutics Llc |
Chimeric antigen receptors (cars) focusing on hematological malignancies, preparations and methods for their use
|
|
WO2016154621A1
(en)
|
2015-03-26 |
2016-09-29 |
The California Institute For Biomedical Research |
SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF
|
|
ES2904573T3
(es)
*
|
2015-03-27 |
2022-04-05 |
Univ Southern California |
Terapia con células T dirigida a LHR para el tratamiento de tumores sólidos
|
|
HUE059218T2
(hu)
|
2015-04-08 |
2022-11-28 |
Novartis Ag |
CD20-terápiák, CD22-terápiák és kombinációs terápiák CD19 kiméra antigénreceptort (CAR-t) expresszáló sejttel
|
|
EP3283113A4
(en)
*
|
2015-04-15 |
2018-12-05 |
The California Institute for Biomedical Research |
Optimized pne-based chimeric receptor t cell switches and uses thereof
|
|
US11896614B2
(en)
|
2015-04-17 |
2024-02-13 |
Novartis Ag |
Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
|
|
EP3286211A1
(en)
|
2015-04-23 |
2018-02-28 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
EP3288570A4
(en)
|
2015-04-29 |
2018-11-21 |
Fred Hutchinson Cancer Research Center |
Modified stem cells and uses thereof
|
|
US11173179B2
(en)
|
2015-06-25 |
2021-11-16 |
Icell Gene Therapeutics Llc |
Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof
|
|
TW202444897A
(zh)
|
2015-06-25 |
2024-11-16 |
美商生物細胞基因治療有限公司 |
嵌合抗原受體(car)、組合物及其使用方法
|
|
SG10201912978PA
(en)
|
2015-07-21 |
2020-02-27 |
Novartis Ag |
Methods for improving the efficacy and expansion of immune cells
|
|
WO2017027392A1
(en)
|
2015-08-07 |
2017-02-16 |
Novartis Ag |
Treatment of cancer using chimeric cd3 receptor proteins
|
|
US11286531B2
(en)
|
2015-08-11 |
2022-03-29 |
The Johns Hopkins University |
Assaying ovarian cyst fluid
|
|
KR102157701B1
(ko)
*
|
2015-08-17 |
2020-09-21 |
서울대학교산학협력단 |
항-코티닌 항체가 연결된 키메라 항체 수용체 및 이의 용도
|
|
US20180243340A1
(en)
*
|
2015-08-24 |
2018-08-30 |
University Of Houston System |
Combination therapy combining car + t cells with appropriately timed immunodulatory antibodies
|
|
CN108780084B
(zh)
|
2015-09-03 |
2022-07-22 |
诺华股份有限公司 |
预测细胞因子释放综合征的生物标志物
|
|
CN108350462B
(zh)
|
2015-09-11 |
2022-05-27 |
生物权威（英国）有限公司 |
嵌合抗原受体及其用途
|
|
EP3352784A4
(en)
|
2015-09-23 |
2019-06-26 |
Cytoimmune Therapeutics, LLC |
FLT3-FACED CAR CELLS FOR IMMUNOTHERAPY
|
|
US12241053B2
(en)
|
2015-10-09 |
2025-03-04 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
|
WO2017075465A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
|
|
WO2017075451A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
|
|
WO2017087708A1
(en)
|
2015-11-19 |
2017-05-26 |
The Brigham And Women's Hospital, Inc. |
Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
|
|
EP3380602A4
(en)
*
|
2015-11-23 |
2019-09-25 |
Trustees of Boston University |
METHOD AND COMPOSITIONS RELATED TO CHIMERIC ANTIGEN RECEPTORS
|
|
CN108699557B
(zh)
|
2015-12-04 |
2025-08-15 |
诺华股份有限公司 |
用于免疫肿瘤学的组合物和方法
|
|
WO2017112784A1
(en)
*
|
2015-12-22 |
2017-06-29 |
The Trustees Of The University Of Pennsylvania |
Spycatcher and spytag: universal immune receptors for t cells
|
|
US20180371052A1
(en)
*
|
2015-12-22 |
2018-12-27 |
Icell Gene Therapeutics Llc |
Chimeric antigen receptors and enhancement of anti-tumor activity
|
|
EP4643874A2
(en)
|
2015-12-22 |
2025-11-05 |
Novartis AG |
Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
|
|
CN108473959B
(zh)
*
|
2016-01-20 |
2023-04-21 |
菲特治疗公司 |
用来在过继性免疫疗法中进行免疫细胞调节的组合物和方法
|
|
EP3405568A4
(en)
|
2016-01-20 |
2019-12-04 |
Fate Therapeutics, Inc. |
COMPOUNDS AND METHODS FOR IMMUNOCELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES
|
|
JP2019508036A
(ja)
*
|
2016-02-16 |
2019-03-28 |
ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド |
免疫療法組成物及び方法
|
|
KR102186180B1
(ko)
*
|
2016-03-17 |
2020-12-03 |
고쿠리츠다이가쿠호우진 야마구치 다이가쿠 |
면역 기능 제어 인자를 발현하는 면역 담당 세포 및 발현 벡터
|
|
WO2017165683A1
(en)
|
2016-03-23 |
2017-09-28 |
Novartis Ag |
Cell secreted minibodies and uses thereof
|
|
JP7282521B2
(ja)
*
|
2016-04-08 |
2023-05-29 |
パーデュー・リサーチ・ファウンデイション |
Ｃａｒ ｔ細胞療法のための方法および組成物
|
|
WO2017192536A1
(en)
|
2016-05-02 |
2017-11-09 |
University Of Kansas |
Eliminating mhc restriction from the t cell receptor as a strategy for immunotherapy
|
|
US20200283534A1
(en)
|
2016-06-24 |
2020-09-10 |
iCell Gene Therapeuticics LLC |
CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS THEREOF
|
|
WO2018049025A2
(en)
|
2016-09-07 |
2018-03-15 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses
|
|
WO2018067991A1
(en)
|
2016-10-07 |
2018-04-12 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
|
CA3039646A1
(en)
|
2016-10-07 |
2018-04-12 |
Novartis Ag |
Chimeric antigen receptors for the treatment of cancer
|
|
AU2017345479B2
(en)
|
2016-10-19 |
2024-03-21 |
The Scripps Research Institute |
Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
|
|
US10617720B2
(en)
|
2016-10-20 |
2020-04-14 |
Miltenyi Biotech, GmbH |
Chimeric antigen receptor specific for tumor cells
|
|
EP3315511A1
(en)
|
2016-10-29 |
2018-05-02 |
Miltenyi Biotec GmbH |
Adapter chimeric antigen receptor expressing cells for targeting of multiple antigens
|
|
WO2018089386A1
(en)
|
2016-11-11 |
2018-05-17 |
The Broad Institute, Inc. |
Modulation of intestinal epithelial cell differentiation, maintenance and/or function through t cell action
|
|
US11261428B2
(en)
|
2018-03-15 |
2022-03-01 |
KSQ Therapeutics, Inc. |
Gene-regulating compositions and methods for improved immunotherapy
|
|
US11332713B2
(en)
|
2016-11-16 |
2022-05-17 |
KSQ Therapeutics, Inc. |
Gene-regulating compositions and methods for improved immunotherapy
|
|
EP3336107A1
(en)
|
2016-12-15 |
2018-06-20 |
Miltenyi Biotec GmbH |
Immune cells expressing an antigen binding receptor and a chimeric costimulatory receptor
|
|
KR102122546B1
(ko)
*
|
2017-01-05 |
2020-06-15 |
한국생명공학연구원 |
항-코티닌 키메릭 항원 수용체를 발현하는 자연살해 세포
|
|
CN110475857B
(zh)
|
2017-01-05 |
2023-07-18 |
韩国生命工学研究院 |
表达抗-可替宁嵌合抗原受体的天然杀伤细胞
|
|
EP3574005B1
(en)
|
2017-01-26 |
2021-12-15 |
Novartis AG |
Cd28 compositions and methods for chimeric antigen receptor therapy
|
|
US11649288B2
(en)
|
2017-02-07 |
2023-05-16 |
Seattle Children's Hospital |
Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
|
|
EP4353818A3
(en)
|
2017-02-27 |
2024-06-19 |
Juno Therapeutics, Inc. |
Compositions, articles of manufacture and methods related to dosing in cell therapy
|
|
WO2018160622A1
(en)
|
2017-02-28 |
2018-09-07 |
Endocyte, Inc. |
Compositions and methods for car t cell therapy
|
|
CN110832075A
(zh)
|
2017-03-22 |
2020-02-21 |
诺华股份有限公司 |
用于免疫肿瘤学的组合物和方法
|
|
WO2018183908A1
(en)
|
2017-03-31 |
2018-10-04 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating ovarian tumors
|
|
WO2018183921A1
(en)
|
2017-04-01 |
2018-10-04 |
The Broad Institute, Inc. |
Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
|
|
AU2018250336B2
(en)
|
2017-04-07 |
2025-02-20 |
Juno Therapeutics, Inc. |
Engineered cells expressing prostate-specific membrane antigen (PSMA) or a modified form thereof and related methods
|
|
US20200071773A1
(en)
|
2017-04-12 |
2020-03-05 |
Massachusetts Eye And Ear Infirmary |
Tumor signature for metastasis, compositions of matter methods of use thereof
|
|
CN110709700A
(zh)
|
2017-04-14 |
2020-01-17 |
朱诺治疗学股份有限公司 |
评估细胞表面糖基化的方法
|
|
AU2018256436B2
(en)
|
2017-04-19 |
2024-12-05 |
Board Of Regents, The University Of Texas System |
Immune cells expressing engineered antigen receptors
|
|
WO2018209324A2
(en)
|
2017-05-11 |
2018-11-15 |
The Broad Institute, Inc. |
Methods and compositions of use of cd8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof
|
|
CA3065133A1
(en)
|
2017-06-09 |
2018-12-13 |
Gemoab Monoclonals Gmbh |
Targeting modules for universal chimeric antigen receptor expressing immune cells and use in the treatment of cancer, infections and autoimmune disorders
|
|
US11897953B2
(en)
|
2017-06-14 |
2024-02-13 |
The Broad Institute, Inc. |
Compositions and methods targeting complement component 3 for inhibiting tumor growth
|
|
US12275787B2
(en)
|
2017-06-21 |
2025-04-15 |
Icell Gene Therapeutics Llc |
Chimeric antigen receptors (CARs), compositions and methods thereof
|
|
US12049643B2
(en)
|
2017-07-14 |
2024-07-30 |
The Broad Institute, Inc. |
Methods and compositions for modulating cytotoxic lymphocyte activity
|
|
WO2019067092A1
(en)
|
2017-08-07 |
2019-04-04 |
The Johns Hopkins University |
METHODS AND SUBSTANCES FOR THE EVALUATION AND TREATMENT OF CANCER
|
|
KR20200055037A
(ko)
*
|
2017-09-19 |
2020-05-20 |
메사추세츠 인스티튜트 오브 테크놀로지 |
키메라 항원 수용체 t 세포 요법을 위한 조성물 및 그의 용도
|
|
WO2019070755A1
(en)
|
2017-10-02 |
2019-04-11 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING A GENETIC SIGNATURE OF IMMUNOTHERAPY RESISTANCE IN CANCER
|
|
CA3079407A1
(en)
|
2017-10-18 |
2019-04-25 |
Novartis Ag |
Compositions and methods for selective protein degradation
|
|
WO2019084055A1
(en)
|
2017-10-23 |
2019-05-02 |
Massachusetts Institute Of Technology |
CLASSIFICATION OF GENETIC VARIATION FROM UNICELLULAR TRANSCRIPTOMS
|
|
US11117936B2
(en)
|
2017-11-10 |
2021-09-14 |
University of Pittsburg—Of the Commonwealth System of Higher Education |
Affinity-enhanced monomeric streptavidin chimeric antigen receptor (CAR)
|
|
WO2019094955A1
(en)
|
2017-11-13 |
2019-05-16 |
The Broad Institute, Inc. |
Methods and compositions for targeting developmental and oncogenic programs in h3k27m gliomas
|
|
WO2019094983A1
(en)
|
2017-11-13 |
2019-05-16 |
The Broad Institute, Inc. |
Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway
|
|
EP3744738A4
(en)
*
|
2017-11-29 |
2021-12-15 |
Guangzhou Cas Lamvac Biotech Co., Ltd. |
CHEMERICAL ANTIGENIC RECEPTOR AND RELATED APPLICATION
|
|
EP3723787A4
(en)
|
2017-12-14 |
2021-09-01 |
Bluebird Bio, Inc. |
DARIC INTERLEUKIN RECEPTORS
|
|
CN111542547B
(zh)
|
2018-01-04 |
2024-02-13 |
美天施生物科技有限两合公司 |
对bdca2抗原具有特异性的嵌合抗原受体
|
|
US11994512B2
(en)
|
2018-01-04 |
2024-05-28 |
Massachusetts Institute Of Technology |
Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
|
|
KR102795692B1
(ko)
|
2018-01-19 |
2025-04-16 |
밀테니 비오텍 비.브이. & 씨오. 케이지 |
키메라 항원 수용체를 발현하는 조절 t 세포
|
|
CN112292138A
(zh)
|
2018-01-22 |
2021-01-29 |
西雅图儿童医院（Dba西雅图儿童研究所） |
Car t细胞的使用方法
|
|
SG11202007426XA
(en)
|
2018-02-06 |
2020-09-29 |
Seattle Childrens Hospital Dba Seattle Childrens Res Inst |
Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors
|
|
EP3755349A4
(en)
|
2018-02-21 |
2021-11-17 |
Board of Regents, The University of Texas System |
PROCESS FOR ACTIVATION AND EXPANSION OF NATURAL KILLER CELLS AND THEIR USES
|
|
WO2019165237A1
(en)
|
2018-02-23 |
2019-08-29 |
Endocyte, Inc. |
Sequencing method for car t cell therapy
|
|
CA3091138A1
(en)
|
2018-02-26 |
2019-08-29 |
Fred Hutchinson Cancer Research Center |
Compositions and methods for cellular immunotherapy
|
|
KR20210006330A
(ko)
|
2018-03-01 |
2021-01-18 |
유니버시티 오브 캔사스 |
재조합 t 세포 수용체 유전자를 사용하여 세포-기반 치료제를 생성하는 기술
|
|
JP7558563B2
(ja)
|
2018-03-15 |
2024-10-01 |
ケーエスキュー セラピューティクス， インコーポレイテッド |
免疫療法の改善のための遺伝子調節組成物及び遺伝子調節方法
|
|
WO2019195586A1
(en)
|
2018-04-06 |
2019-10-10 |
The Regents Of The University Of California |
Methods of treating egfrviii expressing glioblastomas
|
|
WO2019195596A1
(en)
|
2018-04-06 |
2019-10-10 |
The Regents Of The University Of California |
Methods of treating glioblastomas
|
|
US20210155986A1
(en)
|
2018-04-13 |
2021-05-27 |
The Johns Hopkins University |
Non-invasive detection of response to immunotherapy
|
|
US20210079384A1
(en)
|
2018-04-13 |
2021-03-18 |
The Johns Hopkins University |
Non-invasive detection of response to a targeted therapy
|
|
US11957695B2
(en)
|
2018-04-26 |
2024-04-16 |
The Broad Institute, Inc. |
Methods and compositions targeting glucocorticoid signaling for modulating immune responses
|
|
WO2019217913A1
(en)
|
2018-05-10 |
2019-11-14 |
Sensei Biotherapeutics, Inc. |
Aspartate beta-hydroxylase chimeric antigen receptors and uses thereof
|
|
CN112805563B
(zh)
|
2018-05-18 |
2025-06-13 |
约翰·霍普金斯大学 |
用于评估和/或治疗癌症的无细胞dna
|
|
WO2019222642A1
(en)
*
|
2018-05-18 |
2019-11-21 |
Senti Biosciences, Inc. |
Engineered immune cells and methods of use
|
|
WO2019232542A2
(en)
|
2018-06-01 |
2019-12-05 |
Massachusetts Institute Of Technology |
Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
|
|
EP3806888B1
(en)
|
2018-06-12 |
2024-01-31 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
|
MY208825A
(en)
|
2018-06-13 |
2025-05-30 |
Novartis Ag |
Bcma chimeric antigen receptors and uses thereof
|
|
EP3581200A1
(en)
|
2018-06-13 |
2019-12-18 |
GEMoaB Monoclonals GmbH |
Reversed universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
|
|
US12036240B2
(en)
|
2018-06-14 |
2024-07-16 |
The Broad Institute, Inc. |
Compositions and methods targeting complement component 3 for inhibiting tumor growth
|
|
US12466869B2
(en)
|
2018-06-28 |
2025-11-11 |
Dana-Farber Cancer Institute, Inc. |
Targeting of multiple antigens with multiplex CAR T cells in solid and liquid malignancies
|
|
WO2020010229A1
(en)
*
|
2018-07-06 |
2020-01-09 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Car t cell therapy to target t cell specific cancers
|
|
WO2020033927A2
(en)
|
2018-08-09 |
2020-02-13 |
Juno Therapeutics, Inc. |
Processes for generating engineered cells and compositions thereof
|
|
CN110856724B
(zh)
*
|
2018-08-24 |
2022-05-27 |
杭州康万达医药科技有限公司 |
包含核酸及car修饰的免疫细胞的治疗剂及其应用
|
|
EP3620464A1
(en)
|
2018-09-10 |
2020-03-11 |
Miltenyi Biotec GmbH |
Car cell having crosslinked disulfide bridge on antigen recognizing moiety
|
|
JP7504891B2
(ja)
|
2018-09-11 |
2024-06-24 |
ジュノー セラピューティクス インコーポレイテッド |
操作された細胞組成物のマススペクトロメトリー分析のための方法
|
|
KR20210068478A
(ko)
|
2018-09-28 |
2021-06-09 |
메사추세츠 인스티튜트 오브 테크놀로지 |
콜라겐-국재화된 면역조정성 분자 및 그의 방법
|
|
US20210382068A1
(en)
|
2018-10-02 |
2021-12-09 |
Dana-Farber Cancer Institute, Inc. |
Hla single allele lines
|
|
US20220267435A1
(en)
*
|
2018-10-03 |
2022-08-25 |
University Of Pittsburgh-Of The Commonwealth System Of Higher Education |
Covalent adaptor synnotch and chimeric antigen receptors (cars) for programmable antigen-targeting
|
|
US20210379057A1
(en)
|
2018-10-16 |
2021-12-09 |
Massachusetts Institute Of Technology |
Nutlin-3a for use in treating a mycobacterium tuberculosis infection
|
|
WO2020086742A1
(en)
|
2018-10-24 |
2020-04-30 |
Obsidian Therapeutics, Inc. |
Er tunable protein regulation
|
|
US20220170097A1
(en)
*
|
2018-10-29 |
2022-06-02 |
The Broad Institute, Inc. |
Car t cell transcriptional atlas
|
|
CA3117568A1
(en)
|
2018-10-31 |
2020-05-07 |
Juno Therapeutics Gmbh |
Methods for selection and stimulation of cells and apparatus for same
|
|
US12291560B2
(en)
|
2018-12-14 |
2025-05-06 |
Regeneron Pharmaceuticals, Inc. |
Dimerizing agent regulated immunoreceptor complexes
|
|
WO2020131586A2
(en)
|
2018-12-17 |
2020-06-25 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
|
US11739156B2
(en)
|
2019-01-06 |
2023-08-29 |
The Broad Institute, Inc. Massachusetts Institute of Technology |
Methods and compositions for overcoming immunosuppression
|
|
CN111454909B
(zh)
*
|
2019-01-22 |
2024-12-10 |
北京大学深圳研究生院 |
天然配体介导的多靶点识别可调控基因工程化免疫细胞的制备方法
|
|
CN113347991B
(zh)
|
2019-01-23 |
2024-07-30 |
美天施生物科技有限两合公司 |
用于消除和增强受试者骨髓中造血干细胞植入的组合物的组合
|
|
US20220154282A1
(en)
|
2019-03-12 |
2022-05-19 |
The Broad Institute, Inc. |
Detection means, compositions and methods for modulating synovial sarcoma cells
|
|
EP3942023A1
(en)
|
2019-03-18 |
2022-01-26 |
The Broad Institute, Inc. |
Compositions and methods for modulating metabolic regulators of t cell pathogenicity
|
|
WO2020191305A2
(en)
|
2019-03-20 |
2020-09-24 |
Massachusetts Institute Of Technology |
Uses of amphiphiles in immune cell therapy and compositions therefor
|
|
EP3946382A1
(en)
|
2019-04-04 |
2022-02-09 |
UMC Utrecht Holding B.V. |
Modified immune receptor constructs
|
|
BR112021019571A2
(pt)
|
2019-04-19 |
2021-12-07 |
Chugai Pharmaceutical Co Ltd |
Receptor quimérico que reconhece o sítio de modificação do anticorpo
|
|
EP3962519A1
(en)
|
2019-05-01 |
2022-03-09 |
Juno Therapeutics, Inc. |
Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods
|
|
KR20220016475A
(ko)
|
2019-05-01 |
2022-02-09 |
주노 쎄러퓨티크스 인코퍼레이티드 |
변형된 ｔｇｆｂｒ2 유전자 좌에서 재조합 수용체를 발현하는 세포, 관련 폴리뉴클레오티드 및 방법
|
|
MX2021013417A
(es)
|
2019-05-04 |
2021-12-10 |
Inhibrx Inc |
Polipeptidos de union a la proteina del miembro a de la familia 12 del dominio de lectina tipo c (clec12a) y sus usos.
|
|
CN114502586B
(zh)
|
2019-05-08 |
2025-06-24 |
瑞泽恩制药公司 |
Cll-1靶向免疫疗法
|
|
US20220235340A1
(en)
|
2019-05-20 |
2022-07-28 |
The Broad Institute, Inc. |
Novel crispr-cas systems and uses thereof
|
|
CA3142108A1
(en)
|
2019-05-28 |
2020-12-03 |
Miltenyi Biotec B.V. & Co. KG |
Method for generation of genetically modified t cells
|
|
WO2020243371A1
(en)
|
2019-05-28 |
2020-12-03 |
Massachusetts Institute Of Technology |
Methods and compositions for modulating immune responses
|
|
EP3990491A1
(en)
|
2019-06-26 |
2022-05-04 |
Massachusetts Institute of Technology |
Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
|
|
WO2021011781A1
(en)
*
|
2019-07-16 |
2021-01-21 |
The Regents Of The University Of California |
Universal chimeric antigen receptors and methods for making and using them
|
|
WO2021030627A1
(en)
|
2019-08-13 |
2021-02-18 |
The General Hospital Corporation |
Methods for predicting outcomes of checkpoint inhibition and treatment thereof
|
|
US12421557B2
(en)
|
2019-08-16 |
2025-09-23 |
The Broad Institute, Inc. |
Methods for predicting outcomes and treating colorectal cancer using a cell atlas
|
|
US20220298501A1
(en)
|
2019-08-30 |
2022-09-22 |
The Broad Institute, Inc. |
Crispr-associated mu transposase systems
|
|
US20220348937A1
(en)
|
2019-09-06 |
2022-11-03 |
Obsidian Therapeutics, Inc. |
Compositions and methods for dhfr tunable protein regulation
|
|
US20220315894A1
(en)
|
2019-09-11 |
2022-10-06 |
Miltenyi Biotec B.V. & Co. KG |
Method for Transduction of T Cells in the Presence of Malignant Cells
|
|
WO2021061648A1
(en)
|
2019-09-23 |
2021-04-01 |
Massachusetts Institute Of Technology |
Methods and compositions for stimulation of endogenous t cell responses
|
|
US12297426B2
(en)
|
2019-10-01 |
2025-05-13 |
The Broad Institute, Inc. |
DNA damage response signature guided rational design of CRISPR-based systems and therapies
|
|
US12394502B2
(en)
|
2019-10-02 |
2025-08-19 |
The General Hospital Corporation |
Method for predicting HLA-binding peptides using protein structural features
|
|
US12195725B2
(en)
|
2019-10-03 |
2025-01-14 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity
|
|
US11981922B2
(en)
|
2019-10-03 |
2024-05-14 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
|
|
US11793787B2
(en)
|
2019-10-07 |
2023-10-24 |
The Broad Institute, Inc. |
Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
|
|
CA3154281A1
(en)
|
2019-10-16 |
2021-04-22 |
Andrew Scharenberg |
Retroviral vector for universal receptor therapy
|
|
CA3151961A1
(en)
*
|
2019-10-18 |
2021-04-22 |
Mohammadreza PAKYARI |
Cal-t constructs and uses thereof
|
|
US11844800B2
(en)
|
2019-10-30 |
2023-12-19 |
Massachusetts Institute Of Technology |
Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
|
|
PH12022551291A1
(en)
|
2019-11-26 |
2023-11-20 |
Novartis Ag |
Chimeric antigen receptors binding bcma and cd19 and uses thereof
|
|
IL292924A
(en)
|
2019-11-26 |
2022-07-01 |
Novartis Ag |
Cd19 and cd22 chimeric antigen receptors and uses thereof
|
|
US12165747B2
(en)
|
2020-01-23 |
2024-12-10 |
The Broad Institute, Inc. |
Molecular spatial mapping of metastatic tumor microenvironment
|
|
EP4097218A1
(en)
|
2020-01-28 |
2022-12-07 |
Juno Therapeutics, Inc. |
Methods for t cell transduction
|
|
CN115066249A
(zh)
|
2020-02-04 |
2022-09-16 |
美天施生物科技有限两合公司 |
表达用于感测可溶性抗原的适体嵌合抗原受体的免疫细胞
|
|
US20220073977A1
(en)
|
2020-02-14 |
2022-03-10 |
The Johns Hopkins University |
Methods and materials for assessing nucleic acids
|
|
EP3878464A1
(en)
|
2020-03-09 |
2021-09-15 |
Miltenyi Biotec B.V. & Co. KG |
Use of a car cell having crosslinked disulfide bridge on antigen recognizing moiety for targeting cancer cells
|
|
EP4118112A1
(en)
|
2020-03-10 |
2023-01-18 |
Massachusetts Institute of Technology |
Compositions and methods for immunotherapy of npm1c-positive cancer
|
|
KR20240096884A
(ko)
|
2020-03-10 |
2024-06-26 |
매사추세츠 인스티튜트 오브 테크놀로지 |
조작된 기억-유사 nk 세포 및 이의 조성물을 생성하기 위한 방법
|
|
EP3881866A1
(en)
|
2020-03-16 |
2021-09-22 |
GEMoaB GmbH |
A targeting module comprising pd-l1 and/or pd-l2 for use in a method for stimulating a chimeric antigen receptor mediated response in a mammal
|
|
CN115397517A
(zh)
|
2020-04-17 |
2022-11-25 |
希望之城 |
用于治疗flt3阳性恶性肿瘤的靶向flt3的嵌合抗原受体修饰细胞
|
|
US12433954B2
(en)
|
2020-05-01 |
2025-10-07 |
Massachusetts Institute Of Technology |
Methods of activating anti-CD19 chimeric antigen receptor (CAR) T cells using amphiphilic ligand conjugates comprising CAR-targeting protein sequence motifs
|
|
US20210340524A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
|
|
US20230183372A1
(en)
|
2020-05-20 |
2023-06-15 |
Miltenyi Biotec B.V. & Co. KG |
Compositions and Methods for Treating Cancer Expressing CD90 and CD326
|
|
US12286465B2
(en)
|
2020-05-28 |
2025-04-29 |
Miltenyi Biotec B.V. & Co. KG |
Chimeric antigen receptor with a spacer comprising C2-set Ig-like domains
|
|
WO2021260186A1
(en)
|
2020-06-26 |
2021-12-30 |
Juno Therapeutics Gmbh |
Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods
|
|
WO2022015955A1
(en)
|
2020-07-16 |
2022-01-20 |
Umoja Biopharma, Inc. |
Gated adapter targeting receptor
|
|
AU2021317974A1
(en)
|
2020-07-31 |
2023-03-16 |
Chugai Seiyaku Kabushiki Kaisha |
Pharmaceutical Composition comprising Cell Expressing Chimeric Receptor
|
|
WO2022038411A1
(en)
|
2020-08-19 |
2022-02-24 |
Astellas Pharma, Inc. |
Human non-naturally occurring modified fc region of igg specifically binding to non-naturally occurring modified fc receptor
|
|
EP3964585A1
(en)
|
2020-09-03 |
2022-03-09 |
Miltenyi Biotec B.V. & Co. KG |
Cd62l specific lentiviral vector particle for targeted transduction of t cell subsets
|
|
ES2994677T3
(en)
*
|
2020-09-04 |
2025-01-29 |
Miltenyi Biotec Bv & Co Kg |
System for inducible expression of an adapter in immune cells
|
|
EP4228660A4
(en)
*
|
2020-10-14 |
2025-02-26 |
Georgia Tech Research Corporation |
Synthetic antigens as chimeric antigen receptor (car) ligands and uses thereof
|
|
EP4240403A2
(en)
|
2020-11-04 |
2023-09-13 |
Miltenyi Biotec B.V. & Co. KG |
Chimeric antigen receptor comprising an antigen binding domain specific for msln having a specificity for tumor cells
|
|
US20230398148A1
(en)
|
2020-11-04 |
2023-12-14 |
Juno Therapeutics, Inc. |
Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods
|
|
WO2022096664A1
(en)
|
2020-11-09 |
2022-05-12 |
Miltenyi Biotec B.V. & Co. KG |
Methods and compositions for eliminating engineered immune cells
|
|
JP2024500847A
(ja)
*
|
2020-12-18 |
2024-01-10 |
センチュリー セラピューティクス，インコーポレイテッド |
適合可能な受容体特異性を有するキメラ抗原受容体システム
|
|
KR20230159851A
(ko)
|
2021-03-22 |
2023-11-22 |
주노 쎄러퓨티크스 인코퍼레이티드 |
치료 세포 조성물의 효력을 결정하는 방법
|
|
AU2022244229A1
(en)
|
2021-03-22 |
2023-09-14 |
Juno Therapeutics, Inc. |
Method to assess potency of viral vector particles
|
|
WO2022236096A1
(en)
*
|
2021-05-07 |
2022-11-10 |
University Of Florida Research Foundation, Inc. |
Car t cell therapy method
|
|
CN117715655A
(zh)
*
|
2021-06-08 |
2024-03-15 |
生物技术细胞和基因治疗公司 |
用于活化和靶向免疫效应细胞的物质和方法
|
|
CA3227128A1
(en)
*
|
2021-07-28 |
2023-02-02 |
Prescient Therapeutics Ltd |
Universal receptor immune cell therapy
|
|
US20250235477A1
(en)
|
2021-10-06 |
2025-07-24 |
Miltenyi Biotec B.V. & Co. KG |
Method for targeted gene insertion into immune cells
|
|
WO2023062113A1
(en)
|
2021-10-15 |
2023-04-20 |
Miltenyi Biotec B.V. & Co. KG |
Method for the generation of genetically modified nk cells
|
|
WO2023081715A1
(en)
|
2021-11-03 |
2023-05-11 |
Viracta Therapeutics, Inc. |
Combination of car t-cell therapy with btk inhibitors and methods of use thereof
|
|
EP4176895A1
(en)
|
2021-11-08 |
2023-05-10 |
AvenCell Europe GmbH |
Targeting modules against il13ra2 or her2 for use in combination with a chimeric antigen receptor
|
|
US11827716B2
(en)
|
2021-11-15 |
2023-11-28 |
Arcellx, Inc. |
D-domain containing polypeptides and uses thereof
|
|
WO2023107825A1
(en)
*
|
2021-12-07 |
2023-06-15 |
The Regents Of The University Of California |
Synthetic cytokine circuits to promote infiltration and clearance of immune excluded solid tumors by engineered immune cells
|
|
CN118973608A
(zh)
|
2022-04-01 |
2024-11-15 |
美天施生物科技有限两合公司 |
用于多核苷酸的药物诱导型表达的系统
|
|
EP4522751A1
(en)
|
2022-05-10 |
2025-03-19 |
Miltenyi Biotec B.V. & Co. KG |
Compositions comprising il-15, il-15 receptor alpha and the intracellular signaling domain of cd2 for immune cell therapy
|
|
WO2023224715A1
(en)
|
2022-05-19 |
2023-11-23 |
Massachusetts Institute Of Technology |
Car cells targeting an inserted ligand
|
|
WO2024077256A1
(en)
|
2022-10-07 |
2024-04-11 |
The General Hospital Corporation |
Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins
|
|
WO2024078995A1
(en)
|
2022-10-15 |
2024-04-18 |
Miltenyi Biotec B.V. & Co. KG |
Transduction of gammadelta t cells with pseudotyped retroviral vectors
|
|
WO2024124044A1
(en)
|
2022-12-07 |
2024-06-13 |
The Brigham And Women’S Hospital, Inc. |
Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
|
|
CN116041545A
(zh)
*
|
2022-12-12 |
2023-05-02 |
南方医科大学 |
一种靶向荧光素或生物素的通用型car及其应用
|
|
WO2024178397A2
(en)
|
2023-02-24 |
2024-08-29 |
Elevatebio Technologies, Inc. |
Modified immune effector cells and methods of use
|
|
WO2024191918A1
(en)
|
2023-03-10 |
2024-09-19 |
The Regents Of The University Of Colorado, A Body Corporate |
Anti-cd276 and anti-cd99 logic gated chimeric antigen receptors for the treatment of cancer
|
|
WO2024191919A1
(en)
|
2023-03-10 |
2024-09-19 |
The Regents Of The University Of Colorado, A Body Corporate |
Anti-cd56 and anti-cd99 logic gated chimeric antigen receptors for the treatment of cancer
|
|
WO2024220588A1
(en)
|
2023-04-18 |
2024-10-24 |
Juno Therapeutics, Inc. |
Cytotoxicity assay for assessing potency of therapeutic cell compositions
|
|
AU2024261890A1
(en)
|
2023-04-27 |
2025-10-09 |
Miltenyi Biotec B.V. & Co. KG |
Retroviral vector particle pseudotyped with envelope proteins of canine distemper virus
|
|
WO2024223847A1
(en)
|
2023-04-27 |
2024-10-31 |
Miltenyi Biotec B.V. & Co. KG |
Pseudotyped retroviral vector particle with anti-cd3 display
|
|
US20250018037A1
(en)
*
|
2023-05-19 |
2025-01-16 |
Seoul National University R&Db Foundation |
Safety control of switchable chimeric antigen receptor t cells using dose-adjustable adaptors
|
|
WO2024243365A2
(en)
|
2023-05-23 |
2024-11-28 |
Juno Therapeutics, Inc. |
Activation markers of t cells and method for assessing t cell activation
|
|
EP4470555A1
(en)
|
2023-05-31 |
2024-12-04 |
Miltenyi Biotec B.V. & Co. KG |
Anti-tag chimeric antigen receptors with specificity for mutated peptides derived from human fgfr2
|
|
EP4471067A1
(en)
|
2023-06-01 |
2024-12-04 |
Miltenyi Biotec B.V. & Co. KG |
A chemically inducible heterodimerizing system and a method for generation thereof
|
|
AU2024310260A1
(en)
|
2023-06-29 |
2025-12-11 |
Dispatch Biotherapeutics, Inc. |
Synthetic cytokine receptors
|
|
WO2025059533A1
(en)
|
2023-09-13 |
2025-03-20 |
The Broad Institute, Inc. |
Crispr enzymes and systems
|
|
WO2025078492A1
(en)
|
2023-10-13 |
2025-04-17 |
Miltenyi Biotec B.V. & Co. KG |
Cd3-targeted nipah-pseudotyped lentiviral vector particles
|
|
WO2025087935A1
(en)
|
2023-10-26 |
2025-05-01 |
Miltenyi Biotec B.V. & Co. KG |
Chimeric antigen receptor specific for folate receptor 1
|
|
WO2025097055A2
(en)
|
2023-11-02 |
2025-05-08 |
The Broad Institute, Inc. |
Compositions and methods of use of t cells in immunotherapy
|
|
WO2025117544A1
(en)
|
2023-11-29 |
2025-06-05 |
The Broad Institute, Inc. |
Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof
|
|
WO2025125231A1
(en)
|
2023-12-11 |
2025-06-19 |
Miltenyi Biotec B.V. & Co. KG |
Antigen - induced secretion of effector molecules of car t cells
|
|
WO2025149431A1
(en)
|
2024-01-08 |
2025-07-17 |
Miltenyi Biotec B.V. & Co. KG |
Anti cd276 adapter chimeric antigen receptor (car)
|
|
WO2025252325A1
(en)
|
2024-06-06 |
2025-12-11 |
Miltenyi Biotec B.V. & Co. KG |
A human protein scaffold library based on the pdz3 domain of the tight junction protein zo-1
|
|
WO2025252326A1
(en)
|
2024-06-06 |
2025-12-11 |
Miltenyi Biotec B.V. & Co. KG |
A human protein scaffold library based on the n-terminal domain of human fact complex subunit ssrp1
|